Skip to main content

Table 1 Demographic characteristics of the study participants

From: Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D3 as host directed therapy

Characteristics

Placebo (n = 32)

PBA (n = 32)

vitD3 (n = 31)

PBA + vitD3 (n = 32)

Age, years

27.38 ± 8.65

27.72 ± 7.25

25.42 ± 8.15

27.16 ± 8.38

Males

20 (62.50%)

22 (25.90%)

21 (67.70%)

22 (68.80%)

History of contacts

10 (31.30%)

11 (34.40%)

6 (19.40%)

8 (25.00%)

BCG given

22 (68.8%)

19 (59.4%)

26 (83.90%)

23 (71.90%)

Weight, kg

44.75 ± 8.20

45.74 ± 8.91

42.91 ± 8.70

44.00 ± 7.89

Duration of illness, days

48.91 ± 25.42

50.63 ± 21.80

58.39 ± 26.81

52.47 ± 27.58

Vitamin D status

 Deficient, < 30 nmol/L

18 (56%)

23 (71%)

21 (67%)

16 (50%)

 Insufficient, 30–50 nmol/L

10 (31.30%)

6 (18.8%)

5 (16.10%)

12 (37.50%)

 Sufficient, > 50 nmol/L

4 (12.50%)

3 (9.4%)

5 (16.10%)

4 (12.50%)

Baseline clinical score (25)

6.47 ± 0.86

6.45 ± 1.09

6.27 ± 1.01

6.39 ± 0.96

Baseline sputum smear

 < 3 acid-fast bacilli

17 (43.10%)

17 (43.10%)

16 (51.60%)

18 (56.20%)

 > 3 acid-fast bacilli

15 (46.90%)

15 (46.90%)

15 (48.40%)

14 (43.80%)

  1. Data is presented as mean ± standard deviation or number with percentage in parentheses
  2. Abbreviations: BCG Bacillus Calmette–Guérin